<DOC>
	<DOCNO>NCT02073487</DOCNO>
	<brief_summary>Purpose : The purpose study evaluate Pathological Complete Response ( pCR ) breast trastuzumab emtansine ( TDM-1 ) plus Lapatinib plus Abraxane combine newly diagnose HER2 positive breast cancer . This randomized , open label Phase II neo-adjuvant study compare efficacy neoadjuvant Trastuzumab Emtansine ( TDM1 ) plus lapatinib follow Abraxane , versus trastuzumab ( herceptin ) plus Pertuzumab follow paclitaxel .</brief_summary>
	<brief_title>Neoadjuvant TDM1 With Lapatinib Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female gender ; Age ≥18 year ; Performance Status Eastern Cooperative Oncology Group ( ECOG ) 01 Histologically confirm invasive breast cancer : Primary tumor great 1 cm diameter , measure clinical examination mammography ultrasound . Any N , No evidence metastasis ( M0 ) ( isolated supraclavicular node involvement allow ) ; Over expression and/or amplification HER2 invasive component primary tumor confirm certified laboratory prior randomization . Known hormone receptor status . Hematopoietic status : CBC le .75 institutional low limit . Absolute neutrophil count ≥ 1,5 x 10^9/L , Platelet count ≥ 100 x 10^9/L , Hemoglobin least 9 g/dl , Hepatic status : Serum total bilirubin ≤ 2 x upper limit normal ( ULN ) . In case know Gilbert 's syndrome , high serum total bilirubin ( &lt; 1.5 x ULN ) allow , Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 3.5 time ULN , Alkaline phosphatase ≤ 2.5 time ULN , • Renal status : Creatinine ≤ 1.5mg/dL , • Cardiovascular : Baseline leave ventricular ejection fraction ( LVEF ) ³ ≥50 % measure echocardiography ( ECHO ) Multiple Gate Acquisition ( MUGA ) scan , Negative serum urine βhCG pregnancy test screening patient childbearing potential within 2weeks ( preferably 7 day ) prior randomization . Fertile patient must use effective contraception ( barrier method condom , diaphragm also conjunction spermicidal jelly , total abstinence . Oral , injectable , implant hormonal contraceptive allow ) Signed informed consent form ( ICF ) Patient accepts make available tumor sample submission central laboratory conduct translational study part protocol . Previous ( less 5 year ) current history malignant neoplasm , except curatively treat : Basal squamous cell carcinoma skin ; Carcinoma situ cervix . Patients prior malignancy diagnose 5 year prior randomization may enter study . Preexisting peripheral neuropathy ≥ grade 2 Known history uncontrolled symptomatic angina , clinically significant arrhythmia , congestive heart failure , transmural myocardial infarction , uncontrolled hypertension ( ≥180/110 ) , unstable diabetes mellitus , dyspnea rest , chronic therapy oxygen ; Concurrent disease condition would make subject inappropriate study participation serious medical disorder would interfere subject 's safety ; Unresolved unstable , serious adverse event prior administration another investigational drug ; Dementia , alter mental status , psychiatric condition would prevent understand render ICF ; Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . Subjects ulcerative colitis also exclude ; Concurrent neoadjuvant cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy trial therapy ) ; Concurrent treatment investigational agent participation another therapeutic clinical trial ; Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate trastuzumab Emtansine , trastuzumab , lapatinib , paclitaxel , abraxane component ; Pregnant lactate woman ; Concomitant use CYP3A4 inhibitor inducers Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g . active uncontrolled infection , uncontrolled diabetes ) could cause unacceptable safety risk compromise compliance protocol Patients active infection require IV oral antibiotic . Pregnant breastfeed woman Patients unwilling unable comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neoadjuvant Breast Cancer</keyword>
	<keyword>HER2 positive Breast Cancer</keyword>
</DOC>